ENDVENDONOVO THERAPEUTICS, INC.同业对比
ENDONOVO THERAPEUTICS, INC. 与Electromedical & Electrotherapeutic Apparatus的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Electromedical & Electrotherapeutic Apparatus)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENDV本股 | — | — | — | — | 85.2%#3 | -495.0%#13 | -2411.7%#13 | — | — | 4#3 | — | — |
| QTI | $33M#4 | — | 5.1x#8 | 1.7x#3 | 287.9%#2 | -134.6%#11 | -23.4%#6 | -327.1%#10 | -72.2%#4 | 6#1 | 340.4%#2 | — |
| IRIX | $15M#5 | — | 3.1x#7 | 0.3x#1 | — | — | -4.9%#4 | -93.8%#6 | -90.6%#5 | — | -37.5%#6 | — |
| NXL | $8M#6 | — | 2.7x#4 | 25.6x#8 | 78.8%#4 | -8.1%#6 | -2781.7%#14 | -284.9%#8 | — | — | -61.8%#7 | — |
| NDRA | $5M#7 | — | 3.1x#6 | — | — | 38.9%#2 | — | -393.3%#11 | — | — | -12.1%#4 | — |
| NUWE | $5M#8 | 1.4x#1 | 1.9x#3 | 0.6x#2 | -5.4%#11 | -56.9%#9 | -134.3%#8 | -658.4%#12 | -171.4%#7 | — | -99.2%#9 | — |
| ADMT | — | — | — | — | 4.7%#8 | 18.4%#4 | -4.8%#3 | -17.6%#4 | -43.0%#3 | — | — | — |
| ESMC | — | — | — | — | 0.5%#10 | 184.2%#1 | 1.1%#2 | 2.5%#2 | 16.2%#1 | — | — | — |
| FOCL | $239M#2 | — | 23.6x#9 | 3.4x#5 | 1.6%#9 | -42.1%#8 | -35.0%#7 | -289.5%#9 | -137.6%#6 | 3#4 | 401.6%#1 | — |
| GTHP | — | — | — | — | 10857.1%#1 | -32.2%#7 | -309.3%#10 | — | — | 6#1 | — | — |
| HCIL | — | — | — | — | 7.1%#6 | -57.8%#10 | -13.4%#5 | -0.9%#3 | -0.8%#2 | 3#4 | — | — |
| HYPR | $100M#3 | — | 2.9x#5 | 7.4x#6 | 5.2%#7 | 12.6%#5 | -273.4%#9 | -103.5%#7 | -553.0%#8 | — | -13.1%#5 | — |
| INMD | $974M#1 | 10.7x#2 | 1.4x#2 | 2.6x#4 | -6.2%#12 | 22.5%#3 | 23.0%#1 | 29.0%#1 | — | — | 9.2%#3 | — |
| ITOC | $4M#9 | — | 0.7x#1 | 8.4x#7 | 16.7%#5 | -671.7%#14 | -991.7%#11 | -83.3%#5 | — | — | -97.8%#8 | 0.2%#1 |
| POSC | — | — | — | — | -21.5%#13 | -345.7%#12 | -2275.1%#12 | -6604.3%#13 | -3762.9%#9 | 2#6 | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-08-05。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议